Flash News: OKX Enhances OKBund with v0.7 Entrypoint Contracts Support
SINGAPORE, May 7, 2024 /PRNewswire/ -- OKX, a leading Web3 technology company, has issued updates for May 7, 2024.
OKX Enhances OKBund with v0.7 Entrypoint Contracts Support
OKX is thrilled to announce that its 'OKX bundler,' or 'OKBund,' now supports v0.7 Entrypoint contracts. This update facilitates:
Better gas management;
Increased security in blockchain interactions;
Improved tooling and developer experience; and
Support for ERC-7579 and modular smart accounts.
OKBund is a cornerstone of technical infrastructure that allows Account Abstraction (AA) to work on any EVM network. AA simplifies crypto transactions by enabling the creation of Web3 wallet accounts that conceal the more technical details of their on-chain interactions, providing a more accessible and user-centric interface.
Bundlers are special nodes which enable AA by consolidating user operations from multiple senders into a single transaction so they can be executed on a blockchain. Open-source bundlers like OKX's OKBund help to set standards for how the industry puts this technology into practice and ultimately support widespread adoption.
By supporting v0.7 Entrypoint contracts, OKX is once again pushing the boundaries of what's possible in the blockchain space. This development opens up new opportunities for both developers and users, leading the way towards a more accessible and versatile blockchain ecosystem.
A leading global technology company driving the future of Web3, OKX provides a comprehensive suite of products to meet the needs of beginners and experts alike.
To learn more about OKX, download our app or visit: okx.com
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...
After tens of thousands of NYC children were turned away from "Summer Rising," New York City's popular, free summer enrichment program, Brains & Motion launched a campaign offering camps at NYU for a small fraction of the up-to-$1400 per week price...